Impax Asset Management Group plc Has $10.55 Million Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Impax Asset Management Group plc lowered its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 16.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 50,000 shares of the company's stock after selling 10,000 shares during the period. Impax Asset Management Group plc owned 0.17% of Inspire Medical Systems worth $10,552,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Bank of New York Mellon Corp boosted its position in Inspire Medical Systems by 32.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 787,815 shares of the company's stock worth $105,433,000 after acquiring an additional 192,238 shares during the period. William Blair Investment Management LLC grew its position in Inspire Medical Systems by 1.8% in the 2nd quarter. William Blair Investment Management LLC now owns 770,413 shares of the company's stock valued at $103,104,000 after buying an additional 13,602 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Inspire Medical Systems by 51.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company's stock valued at $98,754,000 after buying an additional 156,893 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Inspire Medical Systems by 798.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 267,852 shares of the company's stock valued at $56,530,000 after buying an additional 238,034 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Inspire Medical Systems by 152.7% during the 2nd quarter. AQR Capital Management LLC now owns 231,845 shares of the company's stock worth $31,028,000 after buying an additional 140,090 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of research analyst reports. KeyCorp lowered their price objective on shares of Inspire Medical Systems from $278.00 to $236.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 7th. Robert W. Baird boosted their price objective on Inspire Medical Systems from $240.00 to $252.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Truist Financial reaffirmed a "buy" rating and set a $240.00 target price (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Wells Fargo & Company boosted their price target on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Finally, Leerink Partners upped their price target on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the company a "market perform" rating in a report on Tuesday, September 10th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $227.75.

Inspire Medical Systems Stock Down 0.1 %

Shares of INSP traded down $0.23 during trading hours on Friday, reaching $172.70. The company's stock had a trading volume of 456,729 shares, compared to its average volume of 601,601. The firm has a market cap of $5.18 billion, a price-to-earnings ratio of 161.54 and a beta of 1.36. The company has a 50 day moving average of $202.07 and a two-hundred day moving average of $178.08. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.06 by $0.54. The business had revenue of $203.20 million for the quarter, compared to analysts' expectations of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. Inspire Medical Systems's revenue was up 32.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) EPS. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 1.33 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the transaction, the director now directly owns 23,140 shares in the company, valued at $5,090,800. This trade represents a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.